BR112021026309A2 - Anticorpos para ativação de células t - Google Patents
Anticorpos para ativação de células tInfo
- Publication number
- BR112021026309A2 BR112021026309A2 BR112021026309A BR112021026309A BR112021026309A2 BR 112021026309 A2 BR112021026309 A2 BR 112021026309A2 BR 112021026309 A BR112021026309 A BR 112021026309A BR 112021026309 A BR112021026309 A BR 112021026309A BR 112021026309 A2 BR112021026309 A2 BR 112021026309A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibodies
- antigen
- cell activation
- binds
- binding region
- Prior art date
Links
- 230000006044 T cell activation Effects 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 abstract 4
- 102000036639 antigens Human genes 0.000 abstract 4
- 108091007433 antigens Proteins 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 102000037982 Immune checkpoint proteins Human genes 0.000 abstract 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229940126546 immune checkpoint molecule Drugs 0.000 abstract 1
- 230000003308 immunostimulating effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
anticorpos para ativação de células t. a presente invenção refere-se a anticorpos que incluem uma região de ligação ao antígeno que se liga ao cd137. também são fornecidos neste documento anticorpos biespecíficos que incluem uma primeira região de ligação ao antígeno que se liga a cd137 e uma segunda região de ligação ao antígeno que se liga a uma molécula de ponto de verificação imune, uma molécula imunoestimulatória ou um antígeno tumoral. são fornecidas composições farmacêuticas que incluem os anticorpos e métodos de tratamento do câncer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962866699P | 2019-06-26 | 2019-06-26 | |
US201962953302P | 2019-12-24 | 2019-12-24 | |
PCT/US2020/039218 WO2020263879A1 (en) | 2019-06-26 | 2020-06-24 | Antibodies for t-cell activation |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021026309A2 true BR112021026309A2 (pt) | 2022-06-07 |
Family
ID=74044009
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021026309A BR112021026309A2 (pt) | 2019-06-26 | 2020-06-24 | Anticorpos para ativação de células t |
Country Status (10)
Country | Link |
---|---|
US (2) | US11725058B2 (pt) |
EP (1) | EP3990495A4 (pt) |
JP (1) | JP2022539527A (pt) |
KR (1) | KR20220025739A (pt) |
CN (1) | CN114514244A (pt) |
AU (1) | AU2020308463A1 (pt) |
BR (1) | BR112021026309A2 (pt) |
CA (1) | CA3144617A1 (pt) |
TW (1) | TW202108629A (pt) |
WO (1) | WO2020263879A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202241963A (zh) * | 2021-02-09 | 2022-11-01 | 台灣浩鼎生技股份有限公司 | 新穎醣類抗體、醫藥組成物及其用途 |
AR125753A1 (es) * | 2021-05-04 | 2023-08-09 | Agenus Inc | Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos |
MX2024005999A (es) * | 2021-11-19 | 2024-05-30 | Ap Biosciences Inc | Anticuerpos bispecificos dirigidos a cd137 y usos de los mismos para la inmunoterapia anticancer. |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2284194A1 (en) * | 2004-12-21 | 2011-02-16 | AstraZeneca AB | Antibodies directed to angiopoietin-2 and uses thereof |
EP2111412A2 (en) * | 2007-02-02 | 2009-10-28 | Amgen, Inc | Hepcidin and hepcidin antibodies |
JO3244B1 (ar) * | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
EP3798236B1 (en) | 2011-03-15 | 2022-08-10 | X-Body, Inc. | Antibody screening methods |
AU2012249274A1 (en) | 2011-04-28 | 2013-10-31 | Sloan-Kettering Institute For Cancer Research | Neutralizing antibodies to Nipah and Hendra virus |
CN107353342B (zh) * | 2011-12-05 | 2021-08-10 | X 博迪生物科学公司 | PDGF受体β结合多肽 |
EP4112070A1 (en) * | 2014-04-25 | 2023-01-04 | Dana Farber Cancer Institute, Inc. | Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof |
MX2017010793A (es) | 2015-02-22 | 2018-07-06 | Sorrento Therapeutics Inc | Terapeuticos de anticuerpo que ligan cd137. |
US10688178B2 (en) * | 2015-06-30 | 2020-06-23 | Osaka University | AntiPlexin A1 agonist antibody |
JP7022993B2 (ja) * | 2016-01-11 | 2022-02-21 | インヒブルクス インコーポレイテッド | 多価かつ多重特異性の41bb結合融合タンパク質 |
KR102531889B1 (ko) * | 2016-06-20 | 2023-05-17 | 키맵 리미티드 | 항-pd-l1 및 il-2 사이토카인 |
CN106243223B (zh) * | 2016-07-28 | 2019-03-05 | 北京百特美博生物科技有限公司 | 抗人pdl1抗体及其用途 |
NZ751956A (en) * | 2016-09-23 | 2022-01-28 | Merus Nv | Binding molecules that modulate a biological activity expressed by a cell |
AU2017348475B2 (en) * | 2016-10-30 | 2024-02-08 | Shanghai Henlius Biotech, Inc. | Anti-PD-L1 antibodies and variants |
GB201619648D0 (en) * | 2016-11-21 | 2017-01-04 | Alligator Bioscience Ab | Novel antibodies and uses thereof |
EP3585431A4 (en) * | 2017-02-24 | 2020-12-16 | MacroGenics, Inc. | BISPECIFIC BINDING MOLECULES CAPABLE OF BINDING TO CD137 AND TUMOR ANTIGENS, AND THEIR USES |
US11421040B2 (en) * | 2017-06-02 | 2022-08-23 | Pfizer Inc. | Antibodies specific for FLT3 and their uses |
SG11202000747VA (en) * | 2017-08-01 | 2020-02-27 | Lilly Co Eli | Anti-cd137 antibodies |
EP3470428A1 (en) * | 2017-10-10 | 2019-04-17 | Numab Innovation AG | Antibodies targeting cd137 and methods of use thereof |
US11718679B2 (en) * | 2017-10-31 | 2023-08-08 | Compass Therapeutics Llc | CD137 antibodies and PD-1 antagonists and uses thereof |
TWI701259B (zh) * | 2017-11-09 | 2020-08-11 | 大陸商上海懷越生物科技有限公司 | 4﹘1bb抗體及其製備方法和應用 |
-
2020
- 2020-06-24 AU AU2020308463A patent/AU2020308463A1/en active Pending
- 2020-06-24 JP JP2021576891A patent/JP2022539527A/ja active Pending
- 2020-06-24 TW TW109121449A patent/TW202108629A/zh unknown
- 2020-06-24 CA CA3144617A patent/CA3144617A1/en active Pending
- 2020-06-24 BR BR112021026309A patent/BR112021026309A2/pt unknown
- 2020-06-24 EP EP20831405.4A patent/EP3990495A4/en active Pending
- 2020-06-24 US US16/911,052 patent/US11725058B2/en active Active
- 2020-06-24 WO PCT/US2020/039218 patent/WO2020263879A1/en unknown
- 2020-06-24 CN CN202080045146.1A patent/CN114514244A/zh active Pending
- 2020-06-24 KR KR1020217042095A patent/KR20220025739A/ko unknown
-
2023
- 2023-07-17 US US18/222,763 patent/US20240026018A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
TW202108629A (zh) | 2021-03-01 |
CN114514244A (zh) | 2022-05-17 |
EP3990495A1 (en) | 2022-05-04 |
JP2022539527A (ja) | 2022-09-12 |
CA3144617A1 (en) | 2020-12-30 |
WO2020263879A1 (en) | 2020-12-30 |
KR20220025739A (ko) | 2022-03-03 |
AU2020308463A1 (en) | 2022-02-17 |
US20240026018A1 (en) | 2024-01-25 |
US11725058B2 (en) | 2023-08-15 |
WO2020263879A9 (en) | 2021-12-02 |
US20200407456A1 (en) | 2020-12-31 |
EP3990495A4 (en) | 2023-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112021026309A2 (pt) | Anticorpos para ativação de células t | |
BR112018007046A2 (pt) | anticorpo isolado ou fragmento de ligação a antígeno, composição farmacêutica, molécula de polinucleotídeo isolado, vetor, célula, e, métodos para inibir o crescimento de um tumor ou de uma célula tumoral e para tratar uma doença ou distúrbio. | |
BR112022014667A2 (pt) | Anticorpos de domínio único de cd28 e construtos multivalentes e multiespecíficos dos mesmos | |
CY1123884T1 (el) | Αντισωματα enanti-cd123 και συζευγματα και παραγωγα αυτων | |
BR112017014805A2 (pt) | anticorpos anti-cd3, anticorpos anti-cd123 e anticorpos biespecíficos que se ligam especificamente a cd3 e/ou cd123 | |
BR112021023229A2 (pt) | Conjugados anticorpo-fármaco inibidores de mcl-1 e métodos de uso | |
BR112019003129A2 (pt) | composição compreendendo um domínio de ligação a antígeno que se liga a tigit humano, composição de ácido nucleico e de vetor de expressão, célula hospedeira, e, métodos para preparação de um anticorpo anti-tigit e para tratar cancer. | |
BR112016016207A2 (pt) | Anticorpo anti-pd-l1 isolado ou fragmento de ligação ao antígeno do mesmo, seu método de produção, composição farmacêutica, molécula de polinucleotídeo isolada, vetor, célula, e uso dos mesmos | |
BR112019011186A2 (pt) | conjugado de anticorpo radiomarcado, composto, e, métodos de imageamento e para tratamento de um tumor. | |
BR112018076260A2 (pt) | anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina | |
BR112018075434A2 (pt) | anticorpo isolado ou fragmento de ligação de antígeno do mesmo, composição farmacêutica, e, métodos para tratar câncer e para modular resposta imune antitumor. | |
BR112017027877A2 (pt) | anticorpo monoclonal ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucleico isolado, vetor, célula hospedeira, método para preparar o anticorpo monoclonal ou um fragmento de ligação ao antígeno do mesmo, cepa de célula hibridoma lt005, conjugado, conjugado de anticorpo bifuncional, anticorpo multiespecífico, composição farmacêutica e uso do anticorpo monoclonal ou um fragmento de ligação ao antígeno do mesmo | |
BR112018002451A2 (pt) | estruturas de ligação com antígeno para moléculas alvo | |
UY37591A (es) | Conjugados de fármaco anticuerpo | |
BR112018006237A2 (pt) | proteínas de ligação a pd-1 e métodos de uso das mesmas | |
BR112018014760A2 (pt) | anticorpos anti-ror1, anticorpos biespecíficos para ror1 x cd3 e métodos de uso dos mesmos | |
BR112019000770A2 (pt) | proteínas de ligação semelhantes a anticorpos biespecíficos que se ligam especificamente às cd3 e cd123 | |
BR112018000696A2 (pt) | ?anticorpo, métodos para reduzir e para aumentar a afinidade de ligação de um anticorpo que se liga ao cd3 humano, para tratar e para diagnosticar uma doença, para produzir um anticorpo e para detectar a presença de antígeno de cd3, construto de ácido nucleico, vetor de expressão, célula hospedeira, composição, e, kit? | |
BR112014018481A2 (pt) | anticorpo monoclonal ou policlonal ou um fragmento de ligação a antígeno do mesmo, polinucleotídeo, anticorpo monoclonal, vetor, hibridoma, anticorpo, hibridoma 5166-2 e/ou 5166-9, anticorpo ou fragmento de ligação a antígeno, composição farmacêutica, uso do anticorpo ou fragmento de ligação a anticorpo, método para tratar câncer, método para diagnosticar câncer em um indivíduo, anticorpo, método, composição ou uso | |
BR112018010385A2 (pt) | anticorpo, receptor de antígeno quimérico, ácido nucleico, célula recombinante, processo para produção de um anticorpo ou um receptor de antígeno quimérico, composição, e, método para detecção de uma célula que expressa cll-1, para diagnóstico de uma doença, para inibição de divisão da célula e para tratamento de um câncer. | |
BR112019010595A2 (pt) | anticorpo ou fragmento de ligação ao antígeno do mesmo, combinação de moléculas de ácido nucleico isoladas, composição farmacêutica, kit, e, método para selecionar um composto. | |
BR112017019617A2 (pt) | Anticorpo, composto conjugado anticorpo- fármaco anti-cd48, composição de conjugado anticorpo-fármaco, métodos para tratar um paciente com um câncer que expressa cd48, para produzir um anticorpo anti-cd48 e para produzir um conjugado anticorpo-fármaco anti-cd48, ácido nucléico isolado, vetor isolado, e, célula hospedeira isolada | |
PE20210517A1 (es) | Anticuerpos anti-hla-g y utilizacion de los mismos | |
BR112021008060A2 (pt) | Polipeptídeo, anticorpo anti-ctla4 ou fragmento de anticorpo, imunoconjugado, composição farmacêutica, dose única de composição farmacêutica, método de tratar câncer, e, kit para diagnóstico ou tratamento | |
BR112023000826A2 (pt) | Anticorpo anti-ctla-4 e uso do mesmo |